This issue updates on the company's Medicare application in the U.S., upcoming publication of results from the completed U.S. validation study and the opportunity to watch a filmed company presentation with more information about the complementary opportunities based on the Prostatype® platform that were recently presented.
Content of the newsletter:
- Update on the company’s Medicare process and the U.S.
- U.S. Validation study by Veterans Affairs submitted for publication
- Update on billing of private insurance companies in the U.S.
- Completed investments in the U.S. puts Prostatype Genomics in a strong position
- New commercial opportunities unlocked through earlier R&D investments
- Prostatype Genomics raised SEK 11.5 million through TO5 warrant exercise
Read the full newsletter and subscribe via this link:
https://www.ii.se/en/prostatype-genomics-newsletter-november-2025/
For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
Email: fredrik.rickman@prostatypegenomics.com
Certified Adviser
Tapper Partners AB
Telephone: +46 (0)70 44 010 98
E-mail: ca@tapperpartners.se
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.